Description

The Almag-02 Version 2 uses deep penetrating pulsed magnetic field therapy to target conditions throughout the body.

PEMF, or Pulsed Electromagnetic Field therapy, is a non-invasive method of treating a variety of conditions. The practice was approved by the FDA in 1979 to stimulate growth of bone. In 1991 it was approved for use in the treatment of post-operative edema and pain in superficial soft tissue. In 2004, the FDA approved PEMF for patients at risk for non-fusion, as an adjunct to cervical fusion surgery.

PEMF has been found to be effective and safe, and is often used in patients with long bone fractures. Electromagnetic and magnetic fields are recognized as very promising for a variety of health problems.

The Almag-02 Version 2 is an upgrade from the previous model, and now includes a Local Oscillator. This allows the user to target deep areas.

The depth of penetration is up to 7.8" (20cm), which can reach organs like the pancreas, liver and stomach. The system creates a pulsed magnetic field up to 45 mT. The system allows for zonal and local exposure thanks to having several emitter combinations. You get the basic emitter, a flexible emitter and two coil-inductors for maximum variability.

The number of programs in Version 2 has increased from 50 to 79. Here's a list. This makes the Version 2 much more adaptable and able to treat more conditions than the Version 1. It has ISO and CE approval in Europe and runs on 120V.

The Almag-02 Version 2 has been used for patients with a variety of nervous system disorders, ear, nose and throat diseases, circulatory system diseases, digestive system diseases, skin and tissue problems, connective tissue and musculoskeletal diseases, and genitourinary system diseases. You will want to talk to your health care provider about whether the system is right for you.

The Almag-02 Version 2 is NOT recommended for patients with: systemic blood diseases, coagulopathy and bleeding, malignant neoplasm, cardiac aneurysm, myocardial infarction, severe cardiac arrhythmia, acute hemorrhagic and ischemic stroke, thyrotoxicosis, active tuberculous process, acute infection disease, febrile illness, pregnancy or pacemakers.

It is not contraindicated for those with stents, bypass grafting, or titanium structures.

For rehabilitation after pneumonia, including Pneumonia-COVID-19p Associated

ALMAG-02 is used for the bronchopulmonary diseases treatment:

Chronic bronchitis, excluding acute stage;
Bronchial asthma;
COPD.

As well as for the rehabilitation after bacterial and virus pneumonia, including caused by coronavirus infection COVID-19.

ALMAG-02 can help you to:

Improve microcirculation in lung tissues;
Decrease the probability of formation of connective tissue instead of specific lung tissue during organ regeneration;
Preserve vital capacity of lungs;
Remove shortness of breath;

Complex joint disorders (coxarthrosis, polyarthritis)

ALMAG-02 can simultaneously treat relatively big areas throughout the body and provide deep PEMF penetration to targeted zones. This allows to:

Accelerate reduction of edema and inflammation;
Stimulate the immune system and regeneration processes.

That’s why ALMAG-02 is used for the treatment of such diseases as:

Coxarthrosis;
Polyarthritis;
Ankylosing spondylitis (Bechterew disease);
Osteochondropathy.

To treat COMPLEX joint diseases using ALMAG-02, is EASY:

ALMAG-02 has 2 buttons only: the 1st – for choosing the program number, the 2nd – for activating the program.

Specifications

Voltage: 120/60Hz
Magnetic induction: 2-45 mTI
Pulse repetition frequency: 1-100 Hz
Operation Time: 1-30 minutes depending on program
Treatment programs: 79

Disclaimer: The information on this page is not created to replace the advice of a physician. No statements are intended to treat or diagnose illness. PEMF devices have been given 501(K) clearance by the FDA but the the Almag-02 has not been individually evaluated.

Warranty: Backed by a 100% money back guarantee for two years from the purchase date for proper function. Not responsible for improper usage.